Hidden Variant of ChREBP in Fat Links Lipogenesis to Insulin Sensitivity  by Dentin, Renaud et al.
Cell Metabolism
PreviewsThe work of Haschemi et al. (2012)
provides further evidence of differential
metabolic reprogramming of immune
cells in response to differentiation signals.
These results raise the key question of
whether the metabolic changes in macro-
phages simply reflect a general response
to microbial stimuli or whether metabolic
flux directly influences cellular differentia-
tion programs to shape inflammatory
immune responses. If the latter is true
and metabolic patterning can direct
lineage specification, then how may this
phenomenon occur? Many transcription
factors including NF-kB contain redox-
sensitive Cys residues (Nishi et al., 2002)
and can be influenced by the cellular
redox state. Maintenance of a high
NADH:NAD+ ratio induced by LPS stimu-
lation (and suppressed by CARKL) may
enhance NF-kB binding activity and favor
M1 macrophage differentiation. Another
possibility is that changes in metabolic
flux may influence epigenetic imprinting.
Recent work has shown that metabolicenzymes can affect histone acetylation
and demethylation activity (Lu et al.,
2012; Wellen et al., 2009), which may
impact cell-differentiation programs. It is
unclear whether S7P possesses signaling
properties beyond its role as a PPP
intermediate. Further exploration of how
signal-transduction pathways down-
stream of immune and cytokine receptors
influence cellular metabolism may help us
understand how metabolism may impact
cellular differentiation and effector func-
tion in the immune system.REFERENCES
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The ChREBP transcription factor is regulated by glucose and plays a role in insulin sensitivity, but the mech-
anism underlying these effects remains unclear. In a recent Nature article, Herman et al. (2012) show that
a shorter ChREBP isoform (ChREBP-b) links glucose transport to lipogenesis in white adipose tissue.The quest for the molecular factor medi-
ating the transcriptional effects of glucose
remained unfruitful until ChREBP (carbo-
hydrate responsive element binding
protein) was cloned in 2001 (Yamashita
et al., 2001). Glucose modifies ChREBP
at the posttranslational level (Bricambert
et al., 2010; Guinez et al., 2011) and stim-
ulates its nuclear translocation, therebypromoting binding to a ChREBP binding
site (ChoRE) present on its target genes,
which include glycolytic and lipogenic
genes. The relationship of ChREBP with
insulin resistance is complex: whereas
its inhibition in liver of obese mice
counteracts fatty liver and systemic insulin
resistance (Dentin et al., 2006), ChREBP
overexpression, by modifying hepaticfatty acid composition, promotes a state
of hepatic steatosis that is dissociated
from insulin resistance (Benhamed et al.,
2012). Furthermore, ChREBP is also ex-
pressed in white adipose tissue (WAT),
a target site of insulin resistance in
obesity-related diseases. Decreased
glucose transport and metabolism in
adipocytes together with alterations in15, June 6, 2012 ª2012 Elsevier Inc. 795
Figure 1. ChREBP Exerts Beneficial Effects on Systemic Insulin
Sensitivity through Its Control of de novo Lipogenesis
(A and B) ChREBP expression is reciprocally regulated in white adipose tissue
(WAT) in mouse models of GLUT4 overexpression (GLUT4-OX) and deletion
(GLUT4-KO) (A). Summary of their phenotypes in relationship to lipogenesis
(de novo fatty acid synthesis) or systemic insulin sensitivity is shown (B).
Glucose stimulation induces ChREBP-a, which then transcriptionally activates
ChREBP-b (a shorter and more potent isoform). The beneficial effects of
ChREBP on glucose homeostasis most likely result from upregulation of
lipogenesis in adipose tissue or from the release of beneficial adipokines or
lipokines.
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Previewsthe release of fatty acids,
cytokines, or adipokines are
potential inducers of systemic
insulin resistance, suggesting
a potential role for ChREBP
in this tissue. In a recent
issue of Nature, Herman and
colleagues (Herman et al.,
2012) report that ChREBP
links lipogenesis—de novo
fatty acid synthesis in WAT—
to insulin sensitivity, and
reveal the existence of a
natural ChREBP variant that
may help transmit the tran-
scriptional effects of glucose.
Using mouse models of
adipose specific overexpres-
sion (OX) and deletion (KO)
of the glucose transporter
GLUT4, the authors identify
ChREBP as a key mediator
ofGLUT4effectsandacentral
modulator of lipogenesis in
WAT (Figure 1A). GLUT4-OX
mice show enhanced glucose
tolerance and insulin sensi-
tivity. Even fed with a high-fat
diet (HFD), these mice are
protected against glucose
intolerance, possibly due
to the persistence of WAT
lipogenesis. The induction
of lipogenesis in WAT of
GLUT4-OX mice was abro-
gated, however, when these
mice were crossed with
ChREBP-deficient (ChREBP-
KO) mice. Importantly,GLUT4-OX/ChREBP-KO mice showed
a reversal of enhanced glucose tolerance
and insulin sensitivity that was indepen-
dent of a change in circulating free
fatty acids or an alteration in glucose
transport rates. These results suggest
that beneficial lipids (lipokines) secreted
by adipose tissue upon activation of
lipogenesis can affect whole-body insulin
sensitivity (Cao et al., 2008). In support
of this idea, the authors provide evi-
dence that ChREBP presence correlates
with insulin sensitivity in humans (nondia-
betic and obese patients). The exact
contribution of ChREBP to the pheno-
type of GLUT4-OX mice under HFD will
require further analysis, however. In the
absence of ChREBP, HFD-fed GLUT4-
OX mice would be expected to become
severely glucose and insulin intolerant796 Cell Metabolism 15, June 6, 2012 ª2012due to a marked decrease in WAT
lipogenesis.
An important finding of the study
by Herman and colleagues (Herman et al.,
2012) is the identification of a novel
variant of ChREBP named ChREBP-b.
The authors, with the goal of under-
standing the transcriptional regulation of
ChREBP, searched the ChREBP genomic
region for carbohydrate response ele-
ments (ChoREs), representing potential
ChREBP-binding sites. They found two
such elements, leading them to the
identification of two separate promoters,
corresponding to two variants of
ChREBP: an 864 amino-acid protein
called ChREBP-a, and a 687 amino-acid
protein called ChREBP-b. ChREBP-b
appears to be less abundant than
ChREBP-a but is a potent transactivatorElsevier Inc.exhibiting a transcriptional
activity 20-fold higher than
that of ChREBP-a. Interest-
ingly, the ChREBP-b protein
structure closely resembles
a ChREBP mutant previously
shown to localize to the
nucleus and to activate target
gene expression independent
of glucose concentrations
(CA-ChREBP) (Li et al., 2006).
CA-ChREBP lacks the first
196 amino acids, which in-
clude the low-glucose inhi-
bitory domain (LID). The LID
domain, when present inhi-
bits the glucose response of
ChREBP under low glucose
concentrations. ChREBP-b,
which is missing the first
177 amino acids (most of
the LID), indeed shares
common features with CA-
ChREBP, namely a constitu-
tively high transcriptional
activity. ChREBP-b, but not
ChREBP-a, was highly sen-
sitive to GLUT4-mediated
glucose uptake in WAT. Inter-
estingly, ChREBP-b, but not
ChREBP-a, was decreased
under HFD in subcutaneous
WAT, suggesting that only
this isoform is predictive of
insulin sensitivity in this tissue.
In summary, the work by
Kahn and colleagues demon-
strates that ChREBP is a
central regulator of lipogen-esis in WAT, and that its activity may
promote insulin sensitivity. The authors
had previously proposed that retinol-
binding protein 4, an adipokine, may
mediate whole-body insulin resistance in
GLUT4-KO mice (Yang et al., 2005).
The relationship between ChREBP, WAT
lipogenesis, and retinol-binding protein
was not investigated in the current work,
however. Future lipidomics analyses
may uncover which lipid species act as
the mediators of ChREBP-dependent
insulin sensitivity, and may lead to novel
therapeutic treatments. Researchers
in the field may now also want to
take another look at ChREBP western
blots to check whether they can detect
ChREBP-b at the expected size of
75.5 kDa. The identification of this
new ChREBP variant raises many new
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Previewsquestions. The fact that ChREBP-a does
not upregulate itself but potently induces
expression of ChREBP-b through the
ChoRE sequence identified in exon 1b
implies the existence of a two-step
mechanism in which glucose, perhaps
through a product of glucose metabolism
(potentially glucose 6-phosphate), first
activates ChREBP-a, which would in turn
stimulate ChREBP-b, a much more potent
transcriptional activator (Figure 1B). This
mechanism appears redundant under
physiological conditions and raises
further questions. If one considers that
ChREBP-a is able ‘‘to do the job,’’ why
does it need to induce ChREBP-b to
stimulate similar panels of target genes?
Is ChREBP-b only substantially induced
in case of hyperglycemia as part of
an amplification phenomenon when
ChREBP-a nuclear concentrations reach
sufficient levels? Are ChREBP-a and
ChREBP-b corecruited, in associationwith Mlx (ChREBP heterodimerization
partner (Ma et al., 2006), on the ChoRE of
their target genes? Could ChREBP-a and
ChREBP-b regulate different clusters of
genes by recruiting specific cofactors?
One thing is clear: we still have a lot to
learn about these fascinating transcrip-
tion factors, and selective overexpression
or deletion of ChREBP-a and ChREBP-
b (by targeting exon 1b) coupled with
gene-set analysis could help unravel
their respective physiological and tran-
scriptional functions.REFERENCES
Benhamed, F., Denechaud, P.D., Lemoine, M.,
Robichon, C., Moldes, M., Bertrand-Michel, J.,
Ratziu, V., Serfaty, L., Housset, C., Capeau, J.,
et al. (2012). J. Clin. Invest. Published online May
1, 2012.
Bricambert, J., Miranda, J., Benhamed, F., Girard,
J., Postic, C., and Dentin, R. (2010). J. Clin. Invest.
120, 4316–4331.Cell MetabolismCao, H., Gerhold, K., Mayers, J.R., Wiest, M.M.,
Watkins, S.M., and Hotamisligil, G.S. (2008). Cell
134, 933–944.
Dentin, R., Benhamed, F., Hainault, I., Fauveau, V.,
Foufelle, F., Dyck, J.R., Girard, J., and Postic, C.
(2006). Diabetes 55, 2159–2170.
Guinez, C., Filhoulaud, G., Rayah-Benhamed, F.,
Marmier, S., Dubuquoy, C., Dentin, R., Moldes,
M., Burnol, A.F., Yang, X., Lefebvre, T., et al.
(2011). Diabetes 60, 1399–1413.
Herman, M.A., Peroni, O.D., Villoria, J., Scho¨n,
M.R., Abumrad, N.A., Blu¨her, M., Klein, S., and
Kahn, B.B. (2012). Nature 484, 333–338.
Yamashita, H., Takenoshita, M., Sakurai, M.,
Bruick, R.K., Henzel, W.J., Shillinglaw, W., Arnot,
D., and Uyeda, K. (2001). Proc. Natl. Acad. Sci.
USA 98, 9116–9121.
Li, M.V., Chang, B., Imamura, M., Poungvarin, N.,
and Chan, L. (2006). Diabetes 55, 1179–1189.
Ma, L., Robinson, L.N., and Towle, H.C. (2006).
J. Biol. Chem. 281, 28721–28730.
Yang, Q., Graham, T.E., Mody, N., Preitner, F.,
Peroni, O.D., Zabolotny, J.M., Kotani, K., Quadro,
L., and Kahn, B.B. (2005). Nature 436, 356–362.15, June 6, 2012 ª2012 Elsevier Inc. 797
